Fifthly, Although PD-L1 has emerged as an important target for drug development, and several approved drugs and related clinical trials targeting PD-L1 are available demonstrating the potential of PD-L1 as a drug target, the response rate is still below 40% in most cancer types. This evidence concerns the gene CD274 and cancer.